FDA Grants Fast Track Designation to Kymera Therapeutics, Inc. (KYMR)’s KT-621 for Eosinophilic Asthma

We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. Kymera Therapeutics, Inc. is among the ...

Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined ...

Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and ...

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation ...

GE HealthCare announces first patient dosed in Phase 2/3 LUMINA trial for manganese-based MRI contrast agent under FDA Fast Track designation ...
Healio

FDA grants fast track designation to KT-621 for moderate to severe eosinophilic asthma

The FDA granted fast track designation to KT-621 for treating patients with moderate to severe eosinophilic asthma, according ...
Pharmabiz

Thryv Therapeutics begins patient enrollment in Wave II study for Long QT Syndrome; receives US FDA fast track designation for THRV-1268

Thryv Therapeutics begins patient enrollment in Wave II study for Long QT Syndrome; receives US FDA fast track designation for THRV-1268: San Francisco Saturday, April 25, 2026, 1 ...

Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial

Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, today announced that the U.S. Food and Drug ...

FDA moves to fast-track review of psilocybin and methylone for mental health

Some psychedelic drugs, once considered fringe, are now getting a step closer to possibly being approved for use as mental ...
Seeking Alpha

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

Demonstrates the potential of SGR-1505 as a novel approach for diseases with high unmet medical need NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today announced that SGR-1505, its ...
Targeted Oncology

FDA Grants Fast Track Designation to BBO-11818 in KRAS-Mutant PDAC

FDA fast track designation supports expedited development and regulatory interaction for BBO-11818 in advanced KRAS-mutant ...
Business Wire

Avenzo Therapeutics Granted Fast Track Designation for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with ...

SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the U.S. Food and Drug ...
WFXG

4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis

FDA Fast Track Designation granted to 4P004 for the treatment of knee osteoarthritis, recognizing the disease as a ...